Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

HMB-003

Other · developed by Hemab ApS

Phase 1 Most advanced trial

COAG Developer

1 Registered trials

What is HMB-003?

HMB-003 is an agent administered subcutaneously as a single dose.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Developer: Hemab ApS (COAG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07798505	Phase 1	Healthy Adult Participants	Recruiting	COAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Adult Participants

More from Hemab ApS

HMB-001 Phase 1/2 HMB-002 Phase 1/2 Sutacimig Phase 2

Sources

ClinicalTrials.gov NCT07798505

Updated Oct 11, 2026. Something wrong or missing? Report it on the COAG page.

Follow COAG, the company behind HMB-003

See COAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COAG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z